Literature DB >> 17229088

GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt.

Ayodeji A Asuni1, Claudie Hooper, C Hugh Reynolds, Simon Lovestone, Brian H Anderton, Richard Killick.   

Abstract

In the presence of a Wnt signal beta-catenin is spared from proteasomal degradation through a complex mechanism involving GSK3beta, resulting in the transcription of Wnt target genes. In this study we have explored whether GSK3alpha, a related isoform, can also regulate nuclear beta-catenin levels and whether this and the tau-directed kinase activity of GSK3alpha are modulated by Wnt. GSK3alpha or GSK3beta and their substrates, beta-catenin and tau, were transiently expressed in mammalian cells. Immunoblotting revealed that GSK3alpha reduces nuclear levels of beta-catenin, whilst reporter gene assays demonstrated that GSK3alpha inhibits beta-catenin-directed Tcf/Lef-dependent transcription. Moreover, activation of the Wnt pathway was found to attenuate both the beta-catenin- and the tau-directed kinase activities of GSK3alpha and GSK3beta. By immunoprecipitation we also found that axin-1, the beta-catenin destruction complex scaffold protein, binds GSK3alpha. In the light of these findings GSK3alpha warrants further investigation regarding its involvement in Wnt signalling and tauopathies such as Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17229088     DOI: 10.1111/j.1460-9568.2006.05243.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  20 in total

Review 1.  Osteocytes, mechanosensing and Wnt signaling.

Authors:  Lynda F Bonewald; Mark L Johnson
Journal:  Bone       Date:  2008-01-12       Impact factor: 4.398

2.  Cholecystokinin and Alzheimer's disease: a biomarker of metabolic function, neural integrity, and cognitive performance.

Authors:  Alexandra Plagman; Siobhan Hoscheidt; Kelsey E McLimans; Brandon Klinedinst; Colleen Pappas; Vellareddy Anantharam; Anumantha Kanthasamy; Auriel A Willette
Journal:  Neurobiol Aging       Date:  2019-01-09       Impact factor: 4.673

Review 3.  Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal.

Authors:  Rajat Sandhir; Smriti Gupta
Journal:  World J Diabetes       Date:  2015-09-25

4.  Synaptic stimulation of mTOR is mediated by Wnt signaling and regulation of glycogen synthetase kinase-3.

Authors:  Tao Ma; Nikos Tzavaras; Panayiotis Tsokas; Emmanuel M Landau; Robert D Blitzer
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

5.  Retinoic Acid Receptor α Knockdown Suppresses the Tumorigenicity of Esophageal Carcinoma via Wnt/β-catenin Pathway.

Authors:  Xiao-Mei Mao; Hua Li; Xiao-Yun Zhang; Pan Zhou; Qi-Rui Fu; Qian-En Chen; Jin-Xing Shen; Yu Liu; Qing-Xi Chen; Dong-Yan Shen
Journal:  Dig Dis Sci       Date:  2018-08-28       Impact factor: 3.199

6.  Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.

Authors:  Monica Javidnia; Michaeline L Hebron; Yue Xin; Nikolas G Kinney; Charbel E-H Moussa
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

7.  Quantitative mass spectrometry of diabetic kidney tubules identifies GRAP as a novel regulator of TGF-beta signaling.

Authors:  Timothy D Cummins; Michelle T Barati; Susan C Coventry; Sarah A Salyer; Jon B Klein; David W Powell
Journal:  Biochim Biophys Acta       Date:  2009-10-22

Review 8.  Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis.

Authors:  Scott A Small; Karen Duff
Journal:  Neuron       Date:  2008-11-26       Impact factor: 17.173

Review 9.  Glycogen synthase kinase 3: more than a namesake.

Authors:  Geetha Vani Rayasam; Vamshi Krishna Tulasi; Reena Sodhi; Joseph Alex Davis; Abhijit Ray
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739

10.  Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy.

Authors:  Maj-Linda B Selenica; Milene Brownlow; Jeffy P Jimenez; Daniel C Lee; Gabriela Pena; Chad A Dickey; Marcia N Gordon; Dave Morgan
Journal:  Neurodegener Dis       Date:  2012-07-10       Impact factor: 2.977

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.